600196 复星医药
交易中 02-26 13:32:42
资讯
新帖
简况
复星医药子公司获国家药监局批准Luvometinib片联合安罗替尼开展临床试验
美股速递 · 02-25 17:48
复星医药子公司获国家药监局批准Luvometinib片联合安罗替尼开展临床试验
复星医药子公司药品获新增适应症临床试验批准
财中社 · 02-25 16:50
复星医药子公司药品获新增适应症临床试验批准
复星医药（600196）披露控股子公司盐酸莫托咪酯注射液药品注册申请获受理，2月24日股价下跌0.15%
证券之星 · 02-24 17:56
复星医药（600196）披露控股子公司盐酸莫托咪酯注射液药品注册申请获受理，2月24日股价下跌0.15%
复星医药(02196)：顺铂注射液的药品注册申请获受理
智通财经 · 02-13
复星医药(02196)：顺铂注射液的药品注册申请获受理
复星医药盐酸莫西米德注射液药品注册申请获国家药监局受理
美股速递 · 02-13
复星医药盐酸莫西米德注射液药品注册申请获国家药监局受理
复星医药：公司始终坚持创新驱动发展战略，持续聚焦创新药品和高端器械
证券日报 · 02-11
复星医药：公司始终坚持创新驱动发展战略，持续聚焦创新药品和高端器械
2月10日复星医药现695.41万元大宗交易
证券之星 · 02-10
2月10日复星医药现695.41万元大宗交易
复星医药的“腾笼换鸟”：出清、收购、分拆
蓝鲸财经 · 02-10
复星医药的“腾笼换鸟”：出清、收购、分拆
复星医药子公司盐酸丁卡因凝胶注册申请获受理
财中社 · 02-10
复星医药子公司盐酸丁卡因凝胶注册申请获受理
每周股票复盘：复星医药（600196）发行10亿科技创新债券
证券之星 · 02-08
每周股票复盘：复星医药（600196）发行10亿科技创新债券
群益证券：维持复星医药“买进”评级 授权卫材日本区域斯鲁利单抗权利
智通财经 · 02-06
群益证券：维持复星医药“买进”评级 授权卫材日本区域斯鲁利单抗权利
复星医药子公司复宏汉霖携手卫材就抗PD-1单抗汉斯状 达成日本市场合作
复星医药官微 · 02-05
复星医药子公司复宏汉霖携手卫材就抗PD-1单抗汉斯状 达成日本市场合作
复星医药子公司环磷酰胺注射液药品注册申请获国家药监局受理
美股速递 · 02-05
复星医药子公司环磷酰胺注射液药品注册申请获国家药监局受理
复星医药(02196)：环磷酰胺注射液的药品注册申请获受理
智通财经 · 02-05
复星医药(02196)：环磷酰胺注射液的药品注册申请获受理
复星医药(600196.SH)控股子公司复宏汉霖与Eisai签订许可协议
智通财经 · 02-05
复星医药(600196.SH)控股子公司复宏汉霖与Eisai签订许可协议
复星医药：复迈宁新适应症上市申请获优先审评受理
财中社 · 02-05
复星医药：复迈宁新适应症上市申请获优先审评受理
两会对话｜复星医药文德镛：商保创新药目录落地仍需突破三个瓶颈
澎湃新闻 · 02-05
两会对话｜复星医药文德镛：商保创新药目录落地仍需突破三个瓶颈
复星医药（600196）披露拟分拆子公司复星安特金赴港上市，2月4日股价上涨1.14%
证券之星 · 02-04
复星医药（600196）披露拟分拆子公司复星安特金赴港上市，2月4日股价上涨1.14%
复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务
证券日报 · 02-04
复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务
复星医药完成10亿元科技创新债券发行，发行利率2.4%
财中社 · 02-03
复星医药完成10亿元科技创新债券发行，发行利率2.4%
公司概况
公司名称：
上海复星医药(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1998-08-07
主营业务：
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
发行价格：
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":26.49,"timestamp":1772083962000,"preClose":26.48,"halted":0,"volume":10323126,"delay":0,"changeRate":0.0004,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"交易中","change":0.01,"latestTime":"02-26 13:32:42","open":26.57,"high":26.77,"low":26.48,"amount":275000000,"amplitude":0.011,"askPrice":26.5,"askSize":260,"bidPrice":26.49,"bidSize":170,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772089200000},"marketStatusCode":2,"adr":0,"adjPreClose":26.48,"symbolType":"stock","openAndCloseTimeList":[[1772069400000,1772076600000],[1772082000000,1772089200000]],"highLimit":29.13,"lowLimit":23.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.47,"roa":"--","peRate":21.548849,"roe":"5.3%","epsLYR":1.04,"committee":0.501817,"marketValue":70740000000,"turnoverRate":0.0049,"status":0,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":20.24,"timestamp":1772083958103,"preClose":20.48,"halted":0,"volume":1129000,"delay":0,"premium":"-33.26"},"floatMarketCap":56119000000},"requestUrl":"/m/hq/s/600196/wiki","defaultTab":"wiki","newsList":[{"id":"1199360820","title":"复星医药子公司获国家药监局批准Luvometinib片联合安罗替尼开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1199360820","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199360820?lang=zh_cn&edition=full","pubTime":"2026-02-25 17:48","pubTimestamp":1772012899,"startTime":"0","endTime":"0","summary":"复星医药近日宣布，其子公司已获得国家药品监督管理局（NMPA）的批准，将开展Luvometinib片与安罗替尼联合用药的临床试验。\n此次获批标志着复星医药在肿瘤治疗领域的创新药物研发取得重要进展。Luvometinib片与安罗替尼的联合疗法有望为相关适应症患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0239","BK0183","BK0175","BK0096","BK0028","BK0188","BK0012","BK0187","BK0196","600196"],"gpt_icon":0},{"id":"2614370433","title":"复星医药子公司药品获新增适应症临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2614370433","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614370433?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:50","pubTimestamp":1772009442,"startTime":"0","endTime":"0","summary":"2月25日，复星医药（600196/02196）发布公告，控股子公司复星医药产业近日收到国家药监局关于同意复迈宁?联合安罗替尼用于鼠类肉瘤病毒癌基因（KRAS）突变的晚期非小细胞肺癌患者开展临床试验的批准。复星医药产业计划在条件具备后于中国境内开展该药品的Ⅱ期临床试验。该药品为公司自主研发的创新型小分子化学药物，属于MEK1/2选择性抑制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602253654099292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0060","BK0175","BK0183","BK0188","02196","BK0239","BK0196","BK0096","BK1593","BK0028","BK0187","600196","BK1515","BK1191"],"gpt_icon":0},{"id":"2613479416","title":"复星医药（600196）披露控股子公司盐酸莫托咪酯注射液药品注册申请获受理，2月24日股价下跌0.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613479416","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613479416?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:56","pubTimestamp":1771926988,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，复星医药报收于26.53元，较前一交易日下跌0.15%，最新总市值为708.46亿元。该股当日开盘26.68元，最高26.73元，最低26.51元，成交额达3.26亿元，换手率为0.58%。近日，上海复星医药（集团）股份有限公司控股子公司锦州奥鸿药业有限责任公司提交的盐酸莫托咪酯注射液药品注册申请已获国家药品监督管理局受理，拟定适应症为麻醉诱导和短时手术麻醉。该新药为静脉全身麻醉1类新药，2014年列入“重大新药创制”科技重大专项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400034087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK1515","BK0188","BK0183","02196","BK0096","BK1593","BK1191","BK0175","BK0187","BK0196","BK0028","BK0012","600196"],"gpt_icon":0},{"id":"2611272130","title":"复星医药(02196)：顺铂注射液的药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2611272130","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611272130?lang=zh_cn&edition=full","pubTime":"2026-02-13 17:50","pubTimestamp":1770976252,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，近日，公司控股子公司吉斯美(武汉)制药有限公司就顺铂注射液的药品注册申请获国家药品监督管理局受理。该药品为集团自主研发的化学药品，拟用于治疗转移性睾丸肿瘤、转移性卵巢肿瘤、晚期膀胱癌。截至2026年1月，集团现阶段针对该药品的累计研发投入约为人民币469万元(未经审计)。根据IQVIA CHPA 最新数据，2024年，顺铂注射液于中国境内(不包括港澳台地区)的销售额约为人民币1.65亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK1593","BK0060","02196","BK0239","BK0183","BK1191","BK0096","BK1515","BK0196","BK0187","BK0175","600196","BK0028","BK0188"],"gpt_icon":0},{"id":"1173980735","title":"复星医药盐酸莫西米德注射液药品注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1173980735","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173980735?lang=zh_cn&edition=full","pubTime":"2026-02-13 17:44","pubTimestamp":1770975851,"startTime":"0","endTime":"0","summary":"复星医药宣布，其盐酸莫西米德注射液的药品注册申请已获得国家药品监督管理局（NMPA）正式受理。这一进展标志着该药物在中国市场的注册进程迈出了关键一步，为后续的审评审批奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0028","BK0060","BK0183","BK0187","BK0175","BK0188","BK0196","BK0012","BK0096","BK0239"],"gpt_icon":0},{"id":"2610693091","title":"复星医药：公司始终坚持创新驱动发展战略，持续聚焦创新药品和高端器械","url":"https://stock-news.laohu8.com/highlight/detail?id=2610693091","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610693091?lang=zh_cn&edition=full","pubTime":"2026-02-11 21:05","pubTimestamp":1770815108,"startTime":"0","endTime":"0","summary":"证券日报网讯2月11日，复星医药在互动平台回答投资者提问时表示，公司始终坚持创新驱动发展战略，持续聚焦创新药品和高端器械，并通过不断深化精益运营、持续完善市值管理体系、优化市场沟通机制，推动市场价值与企业内在价值相匹配。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113648144667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","600196","BK0060","BK1191","BK0096","02196","BK0187","BK0175","BK0196","BK1593","BK0183","BK0188","BK0012","BK0239","BK0028"],"gpt_icon":0},{"id":"2610787648","title":"2月10日复星医药现695.41万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2610787648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610787648?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:27","pubTimestamp":1770715662,"startTime":"0","endTime":"0","summary":"证券之星消息，2月10日复星医药发生大宗交易，交易数据如下：大宗交易成交价格27.08元，成交25.68万股，成交金额695.41万元，买方营业部为国泰海通证券股份有限公司总部，卖方营业部为国泰海通证券股份有限公司总部。近三个月该股共发生2笔大宗交易，合计成交5668.0手，折价成交1笔。截至2026年2月10日收盘，复星医药报收于27.08元，上涨0.97%，换手率0.72%，成交量15.34万手，成交额4.15亿元。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000028174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0060","BK0183","BK0188","BK0187","BK0028","BK1191","BK1515","02196","BK1593","BK0196","BK0239","BK0096","600196","BK0012"],"gpt_icon":0},{"id":"2610610481","title":"复星医药的“腾笼换鸟”：出清、收购、分拆","url":"https://stock-news.laohu8.com/highlight/detail?id=2610610481","media":"蓝鲸财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610610481?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:04","pubTimestamp":1770714293,"startTime":"0","endTime":"0","summary":"不得不改变复星医药分拆上市的路径，颇值得玩味。资本运作的两个核心复星医药的“钢丝”，已显而易见。分拆上市的同日，公司公告大股东复星高科技新质押所持股份，用以偿还债务。公司左手出清非核心资产、分拆上市，右手高溢价收购，复杂程度让市场困惑。其实，从出清到收购再到分拆，本质是公司在布局一场精心计算过的“腾笼换鸟”：出清、分拆前景不明的资产换回现金，再逐步拿下绿谷医药的核心资产兑现商业化潜力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1770687870559158944","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0175","BK0060","BK0183","BK0188","BK0187","BK0028","BK1191","BK1515","02196","BK1593","BK0196","BK0239","BK0096","600196","BK0012"],"gpt_icon":0},{"id":"2610617153","title":"复星医药子公司盐酸丁卡因凝胶注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610617153","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610617153?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:42","pubTimestamp":1770712975,"startTime":"0","endTime":"0","summary":"2月10日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获国家药品监督管理局受理。此次申请涉及盐酸丁卡因凝胶，该药品为集团自主研发的化学药品，拟用于经皮局部麻醉，适用于成人及1个月以上的婴儿。至2025年12月，集团针对该药品的累计研发投入约为719万元（未经审计）。根据IQVIACHPA最新数据，2024年该药品在中国境内的销售额约为4.43亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103646706489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0187","BK1593","02196","BK0188","BK0096","BK0183","600196","BK0196","BK0012","BK0028","BK1191","BK1515","BK0175","BK0060"],"gpt_icon":0},{"id":"2609452564","title":"每周股票复盘：复星医药（600196）发行10亿科技创新债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2609452564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609452564?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:56","pubTimestamp":1770486973,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，复星医药报收于26.68元，较上周的26.67元上涨0.04%。本周，复星医药2月5日盘中最高价报26.8元。本周关注点公司公告汇总：复星医药完成发行10亿元科技创新债券，期限2年，利率2.40%。控股子公司复星医药产业自主研发的芦沃美替尼片（复迈宁）用于治疗Ⅰ型神经纤维瘤病成人患者的新增适应症，其上市申请已获国家药监局受理并纳入优先审评程序。截至2025年12月累计研发投入约6.63亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0012","BK0188","BK0196","BK0239","BK1593","BK0175","BK0060","600196","BK0187","02196","BK1191","BK1515","BK0096","BK0028"],"gpt_icon":0},{"id":"2609556567","title":"群益证券：维持复星医药“买进”评级 授权卫材日本区域斯鲁利单抗权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2609556567","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609556567?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:56","pubTimestamp":1770368160,"startTime":"0","endTime":"0","summary":"群益证券发布研报称，预计复星医药(02196)2025-2027年分别实现净利润33.2亿元、46.8亿元、47.7亿元，YOY分别+19.9%、+40.8%、+2.1%，EPS分别为1.2元、1.8元、1.8元，对应H股PE分别为15 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260206/c674613439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["600196","161027"],"gpt_icon":0},{"id":"2609722603","title":"复星医药子公司复宏汉霖携手卫材就抗PD-1单抗汉斯状 达成日本市场合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2609722603","media":"复星医药官微","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609722603?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:11","pubTimestamp":1770293460,"startTime":"0","endTime":"0","summary":"2026年2月5日，上海&东京——卫材株式会社（总部：日本东京，首席执行官：内藤晴夫，以下简称“卫材”）与复宏汉霖（总部：中国上海，首席执行官：朱俊博士）今日共同宣布，双方已就抗P ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260205/c674591094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["600196","BK0187","BK0239","BK0175","BK0183","BK0012","BK0096","BK0196","BK0028","BK0060","BK0188"],"gpt_icon":0},{"id":"1157102696","title":"复星医药子公司环磷酰胺注射液药品注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1157102696","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157102696?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:27","pubTimestamp":1770283630,"startTime":"0","endTime":"0","summary":"复星医药宣布，其子公司提交的环磷酰胺注射液药品注册申请，已正式获得国家药品监督管理局的受理。这一进展标志着该药物在中国市场的注册进程迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0183","BK0028","BK0096","BK0012","BK0175","BK0060","600196","BK0187","BK0196","BK0239"],"gpt_icon":0},{"id":"2609206403","title":"复星医药(02196)：环磷酰胺注射液的药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2609206403","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609206403?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:27","pubTimestamp":1770283627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，近日，公司控股子公司吉斯美(武汉)制药有限公司就环磷酰胺注射液的药品注册申请获国家药品监督管理局受理。据悉，该药品为集团自主研发的化学药品，拟用于治疗患有以下疾病的成人和儿童患者：恶性淋巴瘤、霍奇金病、淋巴细胞性淋巴瘤、混合细胞型淋巴瘤、组织细胞性淋巴瘤、伯基特淋巴瘤、多发性骨髓瘤、白血病、蕈样肉芽肿、神经母细胞瘤、卵巢腺癌、视网膜母细胞瘤、乳腺癌。截至 2025 年 12 月，集团现阶段针对该药品的累计研发投入约为人民币 740 万元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK1191","BK0096","BK0175","BK1515","BK0187","BK0012","BK0196","BK1593","02196","BK0028","BK0183","BK0060","BK0239","600196"],"gpt_icon":0},{"id":"2609322049","title":"复星医药(600196.SH)控股子公司复宏汉霖与Eisai签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2609322049","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609322049?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:46","pubTimestamp":1770281167,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，2026年2月5日，公司控股子公司复宏汉霖与Eisai签订《许可协议》，由复宏汉霖授予Eisai于许可区域(即日本)及领域开发、生产及商业化斯鲁利单抗注射液的权利。基于许可产品于许可区域的年度净销售额达成情况，Eisai应依约向复宏汉霖支付至多23,333万美元的销售里程碑款项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000306685.HKD","BK1191","BK0028","BK0187","02196","600196","BK0183","BK0096","BK1593","BK0175","BK0239","HK0000320223.HKD","BK1161","HK0000320264.USD","BK1515","02696","BK0060","BK0012","BK0188","BK0196","HK0000306701.USD"],"gpt_icon":0},{"id":"2609432214","title":"复星医药：复迈宁新适应症上市申请获优先审评受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2609432214","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609432214?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:43","pubTimestamp":1770280995,"startTime":"0","endTime":"0","summary":"2月5日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获受理。公司控股子公司上海复星医药产业发展有限公司自主研发的复迈宁?（通用名：芦沃美替尼片）用于治疗伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病成人患者的药品上市申请已获国家药品监督管理局受理，并被纳入优先审评程序。截至2025年12月，针对该药品的累计研发投入约为6.63亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642780133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","600196","BK0183","BK0012","02196","BK0175","BK0187","BK1515","BK1593","BK0028","BK0096","BK0188","BK1191","BK0060","BK0196"],"gpt_icon":0},{"id":"2609131245","title":"两会对话｜复星医药文德镛：商保创新药目录落地仍需突破三个瓶颈","url":"https://stock-news.laohu8.com/highlight/detail?id=2609131245","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609131245?lang=zh_cn&edition=full","pubTime":"2026-02-05 07:56","pubTimestamp":1770249406,"startTime":"0","endTime":"0","summary":"“尽管政策取得积极进展，但商保创新药目录的落地和实施仍存在困难。”2月3日，上海市人大代表、复星医药副董事长文德镛在接受澎湃新闻记者独家专访时表达了上述观点。公开数据显示，当前创新药销售费用构成中，基本医疗保险承担44%，商业保险仅承担7%，剩余近半数费用需通过患者自费或其他渠道解决，商保保障效能尚未充分释放。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642106781.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642106781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0239","BK0060","600196","BK0183","BK0012","06978","159992","BK0188","BK1161","BK0196","BK0187","BK0175","BK1515","BK1191","BK0028","BK1593","02196","BK0096"],"gpt_icon":0},{"id":"2608398235","title":"复星医药（600196）披露拟分拆子公司复星安特金赴港上市，2月4日股价上涨1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608398235","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608398235?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:39","pubTimestamp":1770215954,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，复星医药报收于26.64元，较前一交易日上涨1.14%，最新总市值为711.4亿元。该股当日开盘26.35元，最高26.64元，最低26.12元，成交额达3.84亿元，换手率为0.69%。近日，上海复星医药（集团）股份有限公司披露拟分拆所属子公司复星安特金至香港联交所主板上市。公司董事会已审议通过相关议案，提请股东大会审议分拆方案及相关事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0187","BK0060","BK0096","BK1593","BK0188","BK0012","BK1191","BK0175","BK0239","BK0183","BK0028","600196","BK0196","02196"],"gpt_icon":0},{"id":"2608362077","title":"复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362077","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608362077?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:37","pubTimestamp":1770212245,"startTime":"0","endTime":"0","summary":"证券日报网讯2月4日，复星医药在互动平台回答投资者提问时表示，公司自1994年创立于上海，是一家植根中国、创新驱动的全球化医药健康产业集团。目前，公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务；其中，制药是公司的核心主营业务，也是公司品牌建设的重要承载。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043641720167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02196","BK4585","159883","BK1191","BK0096","BK4581","BK0196","BK1583","XLV","BK0175","XBI","BK1574","BK0060","09997","BK0188","LABU","BK0028","BK1222","01477","BK0187","BK1100","09996","BK0012","BK0183","BK1593","BK4588","BK1515","BK0239","159760","600196"],"gpt_icon":0},{"id":"2608829539","title":"复星医药完成10亿元科技创新债券发行，发行利率2.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608829539","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608829539?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:14","pubTimestamp":1770110041,"startTime":"0","endTime":"0","summary":"2月3日，复星医药（600196/02196）发布公告，公司完成2026年度第一期科技创新债券发行，实际发行总额为10亿元，期限为2年，发行利率2.40%。2025年前三季度，复星医药实现收入293.93亿元，归母净利润25.23亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033640171119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4581","600196","BK0028","BK0196","BK0187","BK4585","BK1515","BK0012","BK0188","BK0183","BK1593","02196","BK0175","BK0096","BK1191","BK0060","BK4588"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772083967576,"stockEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0597},{"period":"3month","weight":-0.0268},{"period":"6month","weight":-0.0818},{"period":"1year","weight":0.0647},{"period":"ytd","weight":-0.0004}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0035},{"period":"3month","weight":0.0702},{"period":"6month","weight":0.075},{"period":"1year","weight":0.2394},{"period":"ytd","weight":0.0449}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":" 上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}